long intergenic non-protein coding RNA 2307Genealiases: []
Q-omics provides the consensus-scored LINC02307 profile across patient tissues and cancer cell-line models. LINC02307 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC02307 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, LINC02307 RNA expression shows 6,635 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where LINC02307 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02307 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02307 survival associations across molecular data types. LINC02307 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02307 RNA expression–survival associations across cancer types. High LINC02307 expression shows unfavorable associations in KIRC, HNSC, THCA, STAD, COAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC02307 RNA expression.
This table summarizes LINC02307 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02307. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02307 shows lower tumor expression in THCA and higher tumor expression in LIHC, BRCA and LUAD. The THCA box plot shows higher LINC02307 RNA expression in normal versus tumor tissue (log2 FC = −0.206, t-test p = .002).
This table shows molecular features associated with LINC02307 in patient tissues and cancer cell lines. In patient samples, LINC02307 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
